Character Biosciences, a precision medicine company focused on polygenic diseases, has appointed four senior executives to its leadership team. Those additions are Robert Kim, M.D., MBA as Chief Medical Officer; Daniel Elgort, Ph.D. as Chief Data & Analytics Officer; Josh Buddle as Head of Clinical Network and Longitudinal Research; and Jessamyn Wead as Head of People.
The company also extended its Series B financing, bringing total capital raised in this round to more than USD 110 million, with participation from Sanofi Ventures and other existing and new investors.
Proceeds from the funding extension will be used to further the clinical development of CTX114, a complement inhibitor targeting geographic atrophy, and CTX203, a lipid modulator aimed at preventing progression to advanced age-related macular degeneration, according to the company.
Character Biosciences claims the expanded leadership team and increased funding bolster its capacity to deliver on its mission of transforming outcomes for patients with vision-threatening diseases.
